Human plasma-derived fibrinolysin - Grifols

Drug Profile

Human plasma-derived fibrinolysin - Grifols

Alternative Names: BAY 57-9602; Fibrinolysin-human - Grifols; Plasmin - Grifols; TAL-05-00018

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator Bayer
  • Developer Bausch & Lomb; Grifols
  • Class Serine endopeptidases; Thrombolytics
  • Mechanism of Action Plasmin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral arterial occlusive disorders
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Peripheral arterial occlusive disorders
  • Phase I/II Stroke
  • Discontinued Eye disorders

Most Recent Events

  • 31 Jan 2016 Grifols Therapeutics completes phase II clinical trials in Peripheral arterial occlusive disorders in the US, Belgium, Bulgaria, Czech Republic, Germany, India, Peru, Poland, Romania, Serbia, Spain and Slovakia (Intra-arterial) (NCT01222117)
  • 29 Jul 2015 Phase-I/II development for Stroke is ongoing in Australia, Austria, France, Germany, Serbia, Slovakia, Spain and United Kingdom
  • 29 Jul 2015 Phase-II development for Peripheral arterial occlusive disorders is ongoing in Belgium, Bulgaria, Czech Republic, Germany, India, Peru, Poland, Romania, Serbia, Slovakia, Spain and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top